Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

1 terminated/withdrawn out of 3 trials

Success Rate

50.0%

-36.6% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 2
3(100.0%)
3Total
Phase 2(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT01857817Phase 2Terminated

Efficacy and Safety Study of Etodolac and Propranolol in Patients With Clinically Progressive Prostate Cancer

Role: lead

NCT01265576Phase 2Unknown

Study of Sorafenib With or Without VT-122 in Patients With Hepatocellular Carcinoma (HCC)

Role: lead

NCT00527319Phase 2Completed

Regimen for the Treatment of Cachexia in Subjects With NSCLC

Role: lead

All 3 trials loaded